Product Information
REPAGLINIDE 2 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.0925 per EA under NDC 33342025011. Its NADAC has been published 87 times since Oct 16, 2024.
FDA first approved this application on Mar 22, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342025011
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
REPAGLINIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207209FDA Approved
3/22/2023
TE Code
AB
On Market Since
3/22/2023
Pharmacological Classes
Price Statistics
The NADAC for REPAGLINIDE 2 MG TABLET has been published 87 times since Oct 16, 2024, and over the history we have for it it has declined 20.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0925 per EA |
|---|---|
| All-time high | $0.1186 (Jun 11, 2025) |
| All-time low | $0.0859 (Mar 18, 2026) |
| 52-week high | $0.0966 |
| 52-week low | $0.0859 |
| Median price | $0.0944 |
| Average price | $0.0995 |
| Largest weekly change | +10.7% (Aug 19, 2026) |
| Weeks tracked | 87 |
| Tracking since | Oct 16, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Repaglinide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Glinide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REPAGLINIDE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REPAGLINIDE 2 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.0925 per EA (NDC 33342025011), effective Sep 30, 2026.
How has the price of REPAGLINIDE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for REPAGLINIDE 2 MG TABLET has declined 20.8%. It has been tracked across 87 weekly CMS publications since Oct 16, 2024.
What are the highest and lowest recorded NADAC prices for REPAGLINIDE 2 MG TABLET?
Since Oct 16, 2024, the NADAC for REPAGLINIDE 2 MG TABLET has ranged from a low of $0.0859 (Mar 18, 2026) to a high of $0.1186 (Jun 11, 2025), with a median of $0.0944 per EA.
Are there cheaper alternatives to REPAGLINIDE 2 MG TABLET?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as REPAGLINIDE 2 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures REPAGLINIDE 2 MG TABLET?
REPAGLINIDE 2 MG TABLET (NDC 33342025011) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.